Pfizer’s Paxlovid and Merck & Co’s Molnupiravir are two oral antiviral treatments authorised for patients with mild to moderate COVID-19 symptoms at a high risk of developing severe illness.
BOTHELL, Wash., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three and nine months ended September 30, 2024, ...
The antiviral medication azvudine was approved by the National Health Administration for use in adult patients with COVID-19 in 2022 and is the first domestically produced oral antiviral drug in China ...